IL31RA Gene Amyloidosis Primary Localized Cutaneous Type 2 Genetic Test sale cost 4400 AED
ENAM Gene Amelogenesis Imperfecta Type 1C Genetic Test sale cost 4400 AED ENAM Gene Amelogenesis Imperfecta Type 1C Genetic Test Cost 5,600 د.إ Original price was: 5,600 د.إ.4,400 د.إCurrent price is: 4,400 د.إ.
CASP8 Gene Autoimmune Lymphoproliferative Syndrome Type 2B Genetic Test sale cost 4400 AED CASP8 Gene Autoimmune Lymphoproliferative Syndrome Type 2B Genetic Test Cost 5,600 د.إ Original price was: 5,600 د.إ.4,400 د.إCurrent price is: 4,400 د.إ.
Sale!

IL31RA Gene Amyloidosis Primary Localized Cutaneous Type 2 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The IL31RA Gene Amyloidosis Primary Localized Cutaneous Type 2 Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE. Priced at 4400 AED, this test specifically targets the IL31RA gene to detect mutations associated with Primary Localized Cutaneous Amyloidosis Type 2 (PLCA2), a rare skin disorder. This condition is characterized by the deposition of amyloid proteins in the skin, leading to various dermatological manifestations such as itching, lichen, or macular papules. The genetic test is crucial for confirming the diagnosis, understanding the risk of inheritance, and guiding treatment strategies. By analyzing the patient’s DNA sample, the test can identify specific genetic alterations in the IL31RA gene, providing valuable insights into the condition’s etiology and potential management options. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a significant step towards personalized medicine in dermatology, offering patients and their families critical information for managing PLCA2.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

IL31RA Gene Amyloidosis primary localized cutaneous type 2 Genetic Test

Components:

  • Price: 4400.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Method: NGS Technology
  • Test type: Osteology Dermatology Immunology Disorders
  • Doctor: Dermatologist
  • Test Department: Genetics

Pre Test Information:

Clinical History of Patient who is going for IL31RA Gene Amyloidosis, primary localized cutaneous, type 2 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with IL31RA Gene Amyloidosis, primary localized cutaneous, type 2 NGS Genetic DNA Test gene IL31RA.

Test Details:

IL31RA gene amyloidosis, primary localized cutaneous, type 2 is a rare genetic disorder characterized by the accumulation of amyloid protein in the skin. It is caused by mutations in the IL31RA gene, which provides instructions for making a protein called interleukin-31 receptor A.

NGS (Next-Generation Sequencing) genetic testing is a type of genetic test that uses advanced technology to analyze multiple genes simultaneously. It can detect mutations or changes in the IL31RA gene that are associated with primary localized cutaneous amyloidosis type 2.

The NGS genetic test for IL31RA gene amyloidosis, primary localized cutaneous, type 2 involves obtaining a DNA sample, usually through a blood sample or cheek swab. The DNA is then sequenced using NGS technology to identify any mutations or changes in the IL31RA gene.

This genetic test can help confirm a diagnosis of IL31RA gene amyloidosis, primary localized cutaneous, type 2 in individuals with symptoms suggestive of the condition. It can also be used for carrier testing in individuals with a family history of the disorder or for prenatal testing in families with a known mutation.

The results of the NGS genetic test can provide valuable information for healthcare providers in managing and treating individuals with IL31RA gene amyloidosis, primary localized cutaneous, type 2. It can help guide treatment decisions and provide information about the risk of passing the condition on to future generations.

Test Name IL31RA Gene Amyloidosis primary localized cutaneous type 2 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Osteology Dermatology Immunology Disorders
Doctor Dermatologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for IL31RA Gene Amyloidosis, primary localized cutaneous, type 2 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with IL31RA Gene Amyloidosis, primary localized cutaneous, type 2 NGS Genetic DNA Test gene IL31RA
Test Details

IL31RA gene amyloidosis, primary localized cutaneous, type 2 is a rare genetic disorder characterized by the accumulation of amyloid protein in the skin. It is caused by mutations in the IL31RA gene, which provides instructions for making a protein called interleukin-31 receptor A.

NGS (Next-Generation Sequencing) genetic testing is a type of genetic test that uses advanced technology to analyze multiple genes simultaneously. It can detect mutations or changes in the IL31RA gene that are associated with primary localized cutaneous amyloidosis type 2.

The NGS genetic test for IL31RA gene amyloidosis, primary localized cutaneous, type 2 involves obtaining a DNA sample, usually through a blood sample or cheek swab. The DNA is then sequenced using NGS technology to identify any mutations or changes in the IL31RA gene.

This genetic test can help confirm a diagnosis of IL31RA gene amyloidosis, primary localized cutaneous, type 2 in individuals with symptoms suggestive of the condition. It can also be used for carrier testing in individuals with a family history of the disorder or for prenatal testing in families with a known mutation.

The results of the NGS genetic test can provide valuable information for healthcare providers in managing and treating individuals with IL31RA gene amyloidosis, primary localized cutaneous, type 2. It can help guide treatment decisions and provide information about the risk of passing the condition on to future generations.

SKU: TEST-2839 Category:

Related products